Effect of Roflumilast, a Selective PDE4 Inhibitor, on Bone Phenotypes in ADO2 Mice

• Published in: Calcified tissue international 2024-04, Vol.114 (4), p.419-429
• Main Authors: Alam, Imranul, Hardman, Sara L., Gerard-O’Riley, Rita L., Acton, Dena, Parker, Reginald S., Hong, Jung Min, Bruzzaniti, Angela, Econs, Michael J.
• Format: Article
• Language: English
• Subjects: Animal models; Biochemistry; Biomarkers; Biomedical and Life Sciences; Bone diseases; Bone mineral density; Bone resorption; Cell Biology; Collagen; Computed tomography; Diet; Dual energy X-ray absorptiometry; Endocrinology; Femur; Life Sciences; Missense mutation; Mutation; Original Research; Orthopedics; Osteoclasts; Osteopetrosis; Phenotypes; Phosphodiesterase; Phosphodiesterase IV; Serum levels
• ISSN: 1432-0827; 0171-967X; 1432-0827
• DOI: 10.1007/s00223-023-01180-2

Autosomal Dominant Osteopetrosis type II (ADO2) is a rare bone disease of impaired osteoclastic bone resorption that usually results from heterozygous missense mutations in the chloride channel 7 ( CLCN7 ) gene. We previously created mouse models of ADO2 (p.G213R) with one of the most common mutations (G215R) as found in humans and demonstrated that this mutation in mice phenocopies the human disease of ADO2. Previous studies have shown that roflumilast (RF), a selective phosphodiesterase 4 (PDE4) inhibitor that regulates the cAMP pathway, can increase osteoclast activity. We also observed that RF increased bone resorption in both wild-type and ADO2 heterozygous osteoclasts in vitro , suggesting it might rescue bone phenotypes in ADO2 mice. To test this hypothesis, we administered RF-treated diets (0, 20 and 100 mg/kg) to 8-week-old ADO2 mice for 6 months. We evaluated bone mineral density and bone micro-architecture using longitudinal in-vivo DXA and micro-CT at baseline, and 6-, 12-, 18-, and 24-week post-baseline time points. Additionally, we analyzed serum bone biomarkers (CTX, TRAP, and P1NP) at baseline, 12-, and 24-week post-baseline. Our findings revealed that RF treatment did not improve aBMD (whole body, femur, and spine) and trabecular BV/TV (distal femur) in ADO2 mice compared to the control group treated with a normal diet. Furthermore, we did not observe any significant changes in serum levels of bone biomarkers due to RF treatment in these mice. Overall, our results indicate that RF does not rescue the osteopetrotic bone phenotypes in ADO2 heterozygous mice.